We were excited to hear that Liquidia has filed with the FDA for approval of their drug inhaled treprostinil. They had already reported exciting results with their medication, showing that it was well tolerated and maintained or improved six minute walk distance. Currently, United Therapeutics makes Tyvaso, which is treprostinil for inhalation. Tyvaso … [Read more...]
Acceleron Announces a Positive Trial
PULSAR Phase 2 Study Results This was a very exciting week in the world of pulmonary arterial hypertension. Acceleron announced the results of their PULSAR phase 2 study. This study used Sotatercept, a novel drug, to treat PAH. It was given as a subcutaneous (under the skin) injection every three weeks. The primary endpoint of … [Read more...]
Serotonin and Pulmonary Arterial Hypertension
Serotonin is an important molecule in our bodies. It works in our brain to regulate mood, appetite, sleep, memory and probably many other aspects of our behavior. In the 1960’s and early 1970’s a drug called Aminorex was sold in Europe as a prescription weight loss medication. It was withdrawn from the market in the early 1970’s after doctors … [Read more...]
Getting the Most from the Holiday Season with PAH
The holidays are a time to spend with family and friends and reflect on the past year and think about the upcoming year. This sounds wonderful and low stress. Nothing could be further from the truth. For many people the holiday season is a particularly stressful time of year. While connecting with family can be enjoyable, sometimes our mental … [Read more...]
Pulmonary Hypertension Due To Valvular Heart Disease
As a quick refresher, remember that Pulmonary Hypertension is broadly divided into five groups: Group 1: Pulmonary Arterial Hypertension Group 2: PH due to left heart disease and valvular heart disease Group 3: PH due to chronic lung disease (pulmonary fibrosis or emphysema) Group 4: PH due to chronic blood clots Group 5: PH due to various miscellaneous … [Read more...]